Prediction of venous thromboembolism in cancer patients.

By C. Ay, Daniela Dunkler, C. Marosi, Alexandru Chiriac, R. Vormittag, R. Simanek, P. Quehenberger, C. Zielinski, I. Pabinger. Blood, 2010

761 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. (2021, background): “2%.(244) Parenteral thromboprophylaxis probably results in little to no difference in quality-of-life impairment.”
Epidemiology of cancer-associated venous thrombosis. (2013, methodology): “Ay and colleagues applied this risk model to their prospective observational cohort study of patients with newly diagnosed cancer or with progression of disease after complete or partial remission who had not recently received chemotherapy, surgery, and/or radiotherapy (CATS study).(65) Additionally”
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. (2013, methodology): “Multiple cancer-, treatment-, and patient-related risk factors for VTE relevant to various cancer populations are summarized in Table 3.(91,94-96) Although patients with brain, pancreatic, stomach, kidney, Lyman et al”